相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity
Ildefonso Pulido et al.
JOURNAL OF INFECTION (2012)
Frequency of T Cell Expressing Th1 and Th2 Associated Chemokine Receptor in Patients With Renal Allograft Dysfunction
A. Saxena et al.
TRANSPLANTATION PROCEEDINGS (2012)
Maraviroc intensification for suboptimal CD4+ T cell response in a perinatally HIV-infected adolescent
Maria Espiau et al.
AIDS (2011)
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells
R. Rossi et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
HLA-DR+ CD38+ CD4+ T Lymphocytes Have Elevated CCR5 Expression and Produce the Majority of R5-Tropic HIV-1 RNA In Vivo
Amie L. Meditz et al.
JOURNAL OF VIROLOGY (2011)
Autocrine IL-2 is required for secondary population expansion of CD8+ memory T cells
Sonia Feau et al.
NATURE IMMUNOLOGY (2011)
Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir
Emma Andrews et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2
David M. Asmuth et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
David A. Cooper et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients
Nicholas Funderburg et al.
PLOS ONE (2010)
Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery
Olena Stepanyuk et al.
AIDS (2009)
CCR5 antagonism in HIV infection: ways, effects, and side effects
Pierre Corbeau et al.
AIDS (2009)
The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies
H. Dhami et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation
Jose F. Camargo et al.
JOURNAL OF IMMUNOLOGY (2009)
A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1
Michael Saag et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The biology of CCR5 and CXCR4
Ghalib Alkhatib
CURRENT OPINION IN HIV AND AIDS (2009)
The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5
Yea-Lih Lin et al.
AIDS (2008)
Biology of CCR5 and its role in HIV infection and treatment
Michael M. Lederman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
CCR5 in T cell-mediated liver diseases: What's going on?
Maureen N. Ajuebor et al.
JOURNAL OF IMMUNOLOGY (2006)
The clinical potential of chemokine receptor antagonists
S Ribeiro et al.
PHARMACOLOGY & THERAPEUTICS (2005)
T cell costimulation by chemokine receptors
B Molon et al.
NATURE IMMUNOLOGY (2005)
Immune activation set point during early FHV infection predicts subsequent CD4+ T-cell changes independent of viral load
SG Deeks et al.
BLOOD (2004)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Chemokine receptors: Multifaceted therapeutic targets
AEI Proudfoot
NATURE REVIEWS IMMUNOLOGY (2002)
The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection
F García et al.
AIDS (2001)
CC chemokine receptor 5 and renal-transplant survival
M Fischereder et al.
LANCET (2001)
Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection
M Plana et al.
AIDS (2000)
分享论文
